Early Australian experience with intravascular lithotripsy treatment of severe calcific coronary stenosis: IVL in acute/chronic coronary syndromes.
Journal
AsiaIntervention
ISSN: 2491-0929
Titre abrégé: AsiaIntervention
Pays: France
ID NLM: 101697313
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
20
11
2021
accepted:
24
01
2022
entrez:
30
3
2022
pubmed:
31
3
2022
medline:
31
3
2022
Statut:
ppublish
Résumé
Calcified coronary stenoses are a serious impediment to optimal stent expansion and can lead to stent failure and catastrophic adverse outcomes. We hereby present early Australian experience with intravascular lithotripsy for the treatment of calcific lesions in acute and chronic coronary syndromes. This was a single-centre retrospective study of all patients treated with intravascular lithotripsy (IVL) between October 2019 and June 2021. Patient demographics, procedural variables, and treatment safety/efficacy outcomes were evaluated. During this period, there were 40 patients and 41 coronary lesions with IVL-assisted percutaneous coronary intervention (PCI) (70% male; mean age 72.8±9.5 years). Indications for PCI were acute coronary syndromes in 25 patients (62.5%), and stable angina in 15 patients (37.5%). Upfront IVL usage occurred in 5% of cases with the rest being bailout procedures due to suboptimal initial balloon predilatation or stent underexpansion. Angiographic success (<20% residual stenosis) occurred in 37 cases (92.5%), with mean residual stenosis of 8.25%±8.5%. Two patients experienced procedural complications (5%). IVL appears to be a safe and effective modality in modifying coronary calcium to achieve optimal stent expansion in real-world practice. This device obviates the need for more complex lesion preparation strategies such as rotational or orbital atherectomy.
Identifiants
pubmed: 35350794
doi: 10.4244/AIJ-D-21-00041
pmc: PMC8922461
doi:
Types de publication
Journal Article
Langues
eng
Pagination
42-49Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Catheter Cardiovasc Interv. 2016 Mar;87(4):691-700
pubmed: 26525804
Circ Cardiovasc Interv. 2019 Oct;12(10):e008434
pubmed: 31553205
Heart. 2014 Aug;100(15):1158-64
pubmed: 24846971
Eur Heart J Case Rep. 2020 Jun 09;4(4):1-4
pubmed: 32974451
EuroIntervention. 2017 Aug 25;13(6):696-705
pubmed: 28844031
JACC Cardiovasc Imaging. 2017 Aug;10(8):907-911
pubmed: 28797413
Circ Cardiovasc Interv. 2017 Oct;10(10):
pubmed: 28951394
EuroIntervention. 2019 Oct 20;15(8):714-721
pubmed: 31062700
JACC Cardiovasc Interv. 2014 May;7(5):510-8
pubmed: 24852804
Eur Heart J Case Rep. 2020 Oct 17;4(5):1-4
pubmed: 33204993
Circulation. 1997 Jul 1;96(1):91-8
pubmed: 9236422
J Am Coll Cardiol. 2018 Dec 18;72(24):3126-3137
pubmed: 30261237
JACC Cardiovasc Interv. 2020 Jan 13;13(1):62-71
pubmed: 31918944
Heart. 2007 Dec;93(12):1609-15
pubmed: 17639098
J Am Coll Cardiol. 2014 May 13;63(18):1845-54
pubmed: 24561145
Circ J. 2014;78(9):2209-14
pubmed: 25017740
Circulation. 2019 Feb 5;139(6):834-836
pubmed: 30715944
JACC Cardiovasc Interv. 2020 Jun 22;13(12):1417-1428
pubmed: 32553329
Circulation. 2007 Nov 27;116(22):2634-53
pubmed: 17951284
Catheter Cardiovasc Interv. 2010 May 1;75(6):905-11
pubmed: 20088011
Am J Cardiol. 2002 Nov 15;90(10):1079-83
pubmed: 12423707
J Am Coll Cardiol. 2020 Dec 1;76(22):2635-2646
pubmed: 33069849
J Am Coll Cardiol. 2014 May 6;63(17):1703-14
pubmed: 24530667
Int J Cardiol. 2017 Mar 15;231:61-67
pubmed: 28040289
Heart. 2002 Oct;88(4):401-5
pubmed: 12231603
JACC Cardiovasc Imaging. 2017 Aug;10(8):897-906
pubmed: 28797412
J Interv Cardiol. 2018 Oct;31(5):617-623
pubmed: 29808511